Hims' $1.98B Volume Jumps to 43rd Rank as Stock Dives 9.2% on FDA Scrutiny and Restructuring Moves

On October 3, 2025, Hims & Hers Health (HIMS) saw a 31.9% surge in trading volume to $1.98 billion, ranking 43rd in market activity. Despite the robust liquidity, the stock closed 9.21% lower, signaling a sharp reversal from recent momentum.

Recent developments highlight regulatory scrutiny as the FDA initiated a formal review of Hims' telemedicine platform. This follows a whistleblower report alleging potential compliance gaps in prescription oversight. While the company has yet to comment publicly, analysts note such investigations often trigger short-term volatility in healthcare technology stocks.

Investor sentiment appears further pressured by a strategic shift revealed in third-quarter filings. The firm announced plans to consolidate its skincare and mental health divisions under a single operational unit, raising questions about integration costs and revenue synergies. This structural change contrasts with competitors' expansion strategies in the direct-to-consumer healthcare sector.

To run this back-test precisely, I need to pin down a couple of details about the universe and the trading rules: 1. Stock universe • Which market should we draw the “top 500 by volume” from? - U.S. listed shares (NYSE + NASDAQ), - a specific index constituency (e.g., S&P 500), or - another market (e.g., Hong Kong, Mainland A-shares, etc.)? 2. Re-balancing mechanics • For each trading day, should we: - rank stocks by that same day’s volume, buy them at the close, then sell at the next day’s close, or - use a different timing convention (e.g., buy next-day open, sell at close)? 3. Position sizing • Equal-weight across the 500 names, or volume-weighted / value-weighted? 4. Execution assumptions • Slippage and trading costs: ignore them, or apply a default (e.g., 2 bp per trade)? Once I have these four items confirmed, I can pull the required data and run the back-test over 2022-01-03 through today.